Olverembatinib (HQP1351)
Treatment resistant cancers (e.g., CML, GIST)
RegistrationalActive
Key Facts
Indication
Treatment resistant cancers (e.g., CML, GIST)
Phase
Registrational
Status
Active
Company
About Ascentage Pharma
Ascentage Pharma is a clinical-stage biotech with a unique focus on restoring apoptosis in cancer cells through a portfolio of novel small molecule inhibitors. Its pipeline includes candidates targeting Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2-p53 pathways, as well as next-generation TKIs, with multiple assets in international registrational trials. The company actively seeks global partnerships to accelerate development and commercialization. With a deep scientific foundation and a late-stage clinical pipeline, Ascentage aims to address significant unmet needs in oncology.
View full company profile